All articles by
Amneal announces Zambon as European partner for Parkinson’s drug IPX203
Under the agreement, Italy-based Zambon will seek regulatory approval and market IPX203 in the European Union, UK, and Switzerland for Parkinson’s disease patients
FDA grants Priority Review of AbbVie’s Epcoritamab for R/R follicular lymphoma
AbbVie seeks approval for epcoritamab to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapy and this Priority Review has reduced the review time to just six months
Allecra’s Exblifep secures FDA approval for cUTI treatment
The FDA approved Exblifep (cefepime/enmetazobactam) based on a comprehensive set of clinical data showing the drug’s efficacy against antibiotic resistance in gram-negative bacteria
Nuvalent Receives US FDA Breakthrough Therapy Designation for NVL-520
The BTD for NVL-520 is based on the preliminary safety and activity of NVL-520 in heavily pretreated patients with advanced ROS1-positive NSCLC in the Phase 1 portion of the Phase 1/2 ARROS-1 clinical trial
Pfizer joins hands with NIPER (Ahmedabad) to support healthcare innovation in India
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Roche’s Xolair lowers allergic reactions to multiple foods in NIH study
In the trial, a 16-week course of omalizumab enhanced the quantity of peanut, tree nut, egg, milk, and wheat that multi-food allergic infants as young as one year old could eat without experiencing an allergic reaction
SK bioscience’s SKYTyphoid vaccine secures WHO prequalification
The typhoid vaccine was developed under a collaborative effort between the company and the International Vaccine Institute and had received support from the Bill & Melinda Gates Foundation
Abridge Emerges as a Healthcare AI Leader, Raising $150M to Accelerate R&D
This raise comes just 4 months after their $30M Series B, and is one of the largest funding rounds made to date in generative AI for healthcare
Sentara taps RhythmX AI to improve primary care with generative AI
The collaboration will focus on developing a next-generation, hyper-personalised primary care model for clinicians and patients.
Rigel Pharmaceuticals to buy US rights to Blueprint Medicines’ Gavreto
Blueprint Medicines will be paid a purchase price of $15m, of which $10m is due upon Rigel’s first commercial sale and the remaining $5m is due, subject to certain conditions, on the first anniversary of the closing date